Brand Reference: Remeron
| Metric | Verified Benchmark | Source |
|---|---|---|
| Mirtazapine RxNorm Concept ID | 15996 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.0780 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $36.00 / mo | CMS NADAC + U.S. Retail Markup Index |
| Mark Cuban Cost Plus Wholesale Price | $6.10 / mo | Cost Plus Drugs Wholesale Feed |
| Community Mean Out-of-Pocket Paid | $7.50 / mo | 29 Zero-PHI Verified Patient Logs |
Blocks presynaptic alpha-2 adrenergic autoreceptors and heteroreceptors to boost both norepinephrine and 5-HT1A transmission without touching monoamine transporters, while antagonizing 5-HT2A, 5-HT2C, 5-HT3 (anti-emetic), and H1 receptors—restoring deep sleep and zero sexual dysfunction.
Out-of-pocket price dispersion on Mirtazapine spans $6.10 to $36.00 per 30-day fill: pharmacy acquisition benchmarks sit near $0.0780/unit, allowing cash buyers bypassing PBM spread pricing to retain $29.90 each month (83% reduction).
With 20–40 hours residence kinetics and 50% oral bioavailability, Mirtazapine undergoes cyp1a2, cyp2d6, and cyp3a4 demethylation/hydroxylation and establishes therapeutic activity over 1 hour nocturnal sleep onset; 2–3 weeks mood.
Standard adult regimens span 7.5 mg PO QHS (more sedating via predominant H1), 15 mg PO QHS, 30–45 mg PO QHS (noradrenergic counterbalance reduces sedation). Prescribers screen specifically against maoi within 14 days, while community micro-logs most frequently note carbohydrate appetite & weight increase (38% of reports), morning grogginess at 7.5–15 mg (27% of reports), vivid dreams (16% of reports).
Across 29 verified cash-pay logs, Mirtazapine achieves a 83.90% Worth-It rating with out-of-pocket spend averaging $7.50/mo versus $36.00/mo walk-in retail.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Switched to Cost Plus Drugs at 7.5 mg PO QHS (more sedating via predominant H1) for Mirtazapine; monthly out-of-pocket dropped to $5.37 compared with $36.00 retail.
Completed 10 weeks on Mirtazapine (15 mg PO QHS). Zero notable side effects on steady dosing.
Consistent biomarker response on 30–45 mg PO QHS (noradrenergic counterbalance reduces sedation) Mirtazapine sourced via Cost Plus Drugs ($7.08/mo cash pay without insurance prior authorization).